JPH01207229A - Suppository - Google Patents
SuppositoryInfo
- Publication number
- JPH01207229A JPH01207229A JP3236688A JP3236688A JPH01207229A JP H01207229 A JPH01207229 A JP H01207229A JP 3236688 A JP3236688 A JP 3236688A JP 3236688 A JP3236688 A JP 3236688A JP H01207229 A JPH01207229 A JP H01207229A
- Authority
- JP
- Japan
- Prior art keywords
- suppositories
- suppository
- base
- layer
- pigment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000829 suppository Substances 0.000 title claims abstract description 60
- 239000000049 pigment Substances 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 abstract description 6
- 239000002245 particle Substances 0.000 abstract description 4
- 238000003908 quality control method Methods 0.000 abstract description 4
- 239000007787 solid Substances 0.000 abstract description 4
- 239000010410 layer Substances 0.000 description 30
- 239000000975 dye Substances 0.000 description 12
- 239000003086 colorant Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000002511 suppository base Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920000260 silastic Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000017317 Fortunella Nutrition 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- WPPDXAHGCGPUPK-UHFFFAOYSA-N red 2 Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=2C=3C4=CC=C5C6=CC=C7C8=C(C=9C=CC=CC=9)C9=CC=CC=C9C(C=9C=CC=CC=9)=C8C8=CC=C(C6=C87)C(C=35)=CC=2)C4=C1C1=CC=CC=C1 WPPDXAHGCGPUPK-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は坐剤、更に詳細には特に多層坐剤にした場合に
各層の境界面が明瞭となり、品質管理が簡便にできる等
の優れた坐剤に関するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention provides suppositories, and more specifically, when made into multilayer suppositories, the boundaries between each layer are clear and quality control can be easily performed. It concerns suppositories.
従来よシ広く使用されている坐剤は、基剤として脂肪酸
トリグリセライドを主成分とする常温固型の油脂性基剤
に一種もしくは二種以上の薬効成分を配合混和した単層
坐剤が一般的である。Suppositories that have been widely used in the past are generally single-layer suppositories, which are made by blending one or more medicinal ingredients into an oily base that is solid at room temperature and whose main ingredient is fatty acid triglyceride. It is.
ところで近年、ドラッグデリバリ−システムの考え方か
ら、各種の多層坐剤が考案されている。すなわち、異な
る融点の基剤を多層坐剤に用いることにより経時的な坐
剤からの薬物の放出性を持続化させたり、あるいは種々
の増粘剤をある層に添加し、その層の薬物のみの放出音
おくらせたシ、また、カシロン酸ナトリウムやサリチル
酸ナトリウムのごとき、吸収促進剤をある層のみに添加
し、その層の薬物のみの吸収性金高める等の工夫がされ
ている。Incidentally, in recent years, various multilayer suppositories have been devised from the concept of drug delivery systems. That is, by using base materials with different melting points in a multilayer suppository, the release of the drug from the suppository over time can be sustained, or by adding various thickeners to a certain layer, only the drug in that layer can be used. Efforts have also been made to delay the release sound of the drug, and to add absorption enhancers such as sodium cassilonate and sodium salicylate only to certain layers to increase the absorption of the drug only in that layer.
しかしながら、従来の坐剤、特に多層坐剤においてはい
くつかの問題があった。すなわち、一般に多層坐剤は、
加熱溶融した第1基剤を坐剤成形容器に注入し、冷却固
化あるいは半固化状にした後に再び加熱溶融させた第2
基剤金ひき続き注入し、冷却するという操作をくり返す
ことにより製造されるが、このように製造された多層坐
剤では各層の他層との境界が不明確であるため製造上の
管理がゆきとどかないことが多い。例えば各層の注入が
スムーズにゆかず、かたよってしまったり、また境界面
が混合してしまう等の不良品が発生する。ところが、一
般に多層坐剤の各層は同一の基剤を用いるため、外観上
区別しにくいことから、かかる不良品の発生防止の管理
が十分でない。However, there have been several problems with conventional suppositories, particularly multilayer suppositories. That is, multilayer suppositories generally have
The heated and melted first base is poured into a suppository molding container, cooled to solidify or semi-solidified, and then heated and melted again.
It is manufactured by repeatedly injecting base gold and cooling it, but in multilayer suppositories manufactured in this way, the boundaries between each layer and other layers are unclear, making manufacturing control difficult. It often doesn't make it all the way. For example, the injection of each layer does not proceed smoothly, resulting in uneven products, or the interfaces are mixed, resulting in defective products. However, since each layer of a multilayer suppository generally uses the same base material, it is difficult to distinguish them in terms of appearance, and therefore, there is insufficient control to prevent the occurrence of such defective products.
また坐剤は概して白色の砲弾型をしており、外観的に区
別がつけにくく、2種以上の坐剤全取り扱う場合誤用の
おそれもある。Additionally, suppositories are generally white and bullet-shaped, making them difficult to distinguish visually, and there is a risk of misuse when handling two or more types of suppositories.
これらの問題点を解決する手段として錠剤等の他の製剤
同様坐剤に着色するということが提案されている。着色
剤としては例えば青紫色の消炎剤であるアズレンや黄色
のレシチン等が用いられる。これらの着色剤は油溶性で
あるため、油脂性基剤を均一に着色することができるが
、多層坐剤においては保管中にある特定の層から他の層
への移動が生じ、十分な効果を発揮することができなか
った。As a means to solve these problems, it has been proposed to color suppositories like other preparations such as tablets. As the coloring agent, for example, azulene, which is a bluish-purple anti-inflammatory agent, and yellow lecithin are used. Since these colorants are oil-soluble, they can uniformly color the oil-based base, but in multilayer suppositories, migration from one specific layer to another occurs during storage, resulting in insufficient effect. I was unable to demonstrate my potential.
従って、各層の境界が明確であり、品質管理が容易にで
きかつ、長期に安定な着色坐剤の開発が熱望されていた
。Therefore, there has been a desire to develop colored suppositories that have clear boundaries between layers, can be easily controlled for quality, and are stable over a long period of time.
そこで本発明者らはかかる従来の坐剤の欠点全克服すべ
く鋭意研究した結果、油脂性基剤に不溶性の色素を油脂
性基剤中に均一に分散させた基剤を用いた坐剤は、均一
に着色が可能であるばかりでなく、多層坐剤の場合には
各層間での色素の移動が認められず、充填時の品質管理
が容易となシ%誤用も防止できることを見い出し、本発
明全完成した。Therefore, the present inventors conducted extensive research to overcome all the drawbacks of conventional suppositories, and as a result, a suppository using a base in which pigments that are insoluble in an oil-based base are uniformly dispersed in an oil-based base has been developed. They discovered that not only can coloring be uniform, but also that in the case of multilayer suppositories, there is no movement of pigment between the layers, making it easier to control quality during filling and prevent misuse of pigments. The invention is complete.
すなわち本発明は油脂性基剤よりなる坐剤において、該
油脂性基剤に不溶性の色素を均一に分散せしめたことを
特徴とする坐剤を提供するものである。That is, the present invention provides a suppository made of an oleaginous base, characterized in that an insoluble pigment is uniformly dispersed in the oleaginous base.
本発明に用いられる基剤は、常温で固形状であって油脂
性であれば特に制限されないが、例えばカカオ脂、ラノ
リン脂、インカカオ■(花王製)、ウィテゾゾル■(ダ
イナミックノーベル社製)、す?シア■(ガッテフォッ
セ社)、SB■(鐘渕化学工業製)、ファー−ゾル■(
日本油脂裂)等の局外規ハードファツトが挙げられる。The base used in the present invention is not particularly limited as long as it is solid at room temperature and oily. ? Shea ■ (Gattefosse), SB ■ (manufactured by Kanebuchi Chemical Industry Co., Ltd.), Fur-Sol ■ (
Examples include non-regular hard fats such as Nippon Oil & Fats.
本発明において油脂性基剤に不溶性とは、油脂性基剤が
固形状態、溶融状態いずれの場合にも、油脂性基剤に相
溶しないことをいう。In the present invention, "insoluble in an oleaginous base" means that it is not compatible with the oleaginous base, whether the oleaginous base is in a solid state or in a molten state.
かかる色素としては、好ましいものとしてタール系色素
が挙げられ、具体的には赤色2゜3.102.104.
105.106,201.202.203.204.2
05,206、207、208、213、214. 2
15.218. 219. 220. 221. 22
3.225、 226. 227. 228.230゜
231.232号、黄色4.5.201.202.20
3.204.205号、緑色3.201.202.20
4,2Q5号、だいだい色201.203.204,2
05.206.207号、青色1.2,201,202
゜203.204,205号、かっ色201号、紫色2
01号等金挙げることができる。Preferred examples of such dyes include tar-based dyes, specifically red 2°3.102.104.
105.106, 201.202.203.204.2
05, 206, 207, 208, 213, 214. 2
15.218. 219. 220. 221. 22
3.225, 226. 227. 228.230゜231.232, yellow 4.5.201.202.20
No. 3.204.205, green 3.201.202.20
4,2Q5, orange 201.203.204,2
No. 05.206.207, Blue 1.2, 201, 202
゜203.204,205, brown color 201, purple 2
Gold such as No. 01 can be mentioned.
これらタール系色素は日本において医薬品への着色剤と
しての使用が認められており、油脂性基剤に対し通常0
.001〜LO重量悌。These tar-based pigments are approved for use as coloring agents in pharmaceuticals in Japan, and are usually used as colorants for oil-based bases.
.. 001~LO weight.
好ましくは0001〜001重量係添加される0
なお、本発明に用いる色素は、平均粒径50μ以下、特
に10μ以下であることが好ましい。粒径が大きい場合
は着色が不均一となり好ましくない。Preferably, the weight ratio of 0001 to 001 is added. The dye used in the present invention preferably has an average particle size of 50 μm or less, particularly 10 μm or less. If the particle size is large, the coloring will be uneven, which is not preferable.
また本発明の坐剤に配合される薬効成分としては、従来
坐剤に用いられているものであれば特に制限されないが
、痔疾用坐剤としては酢酸ヒドロコーチシン、酢酸ゾレ
ドニゾロン等のステロイド;リドカイン、ゾブカイン等
の局所麻酔剤:セトリシドや塩酸クロルヘキシシン等の
殺菌剤;ビタミンE等のビタミン剤;酸化亜鉛等の止血
剤;アラントインおよびその誘導体等を挙げることがで
きる。また痔疾用坐剤以外の坐剤の薬効成分の例として
は、インドメタシン、アスピリン等の非ステロイド系解
熱鎮痛消炎剤;フェノパルビタールナトリウム等の催眠
鎮静剤;トンペリトン等の鎮吐剤:臭化プチルスコ?ラ
ミン等の鎮痙剤;グリセリン等の下剤;ゾゾロフイリン
等の鎮咳去痰剤;テガフール等の抗悪性腫瘍剤等が挙げ
られる。The medicinal ingredients to be incorporated into the suppositories of the present invention are not particularly limited as long as they are those conventionally used in suppositories, but for hemorrhoid suppositories steroids such as hydrocortisone acetate and zolednisolone acetate; , local anesthetics such as zobucaine; bactericidal agents such as cetricide and chlorhexicine hydrochloride; vitamins such as vitamin E; hemostatic agents such as zinc oxide; allantoin and its derivatives. In addition, examples of medicinal ingredients of suppositories other than those for hemorrhoids include nonsteroidal antipyretic, analgesic, and antiinflammatory agents such as indomethacin and aspirin; hypnotic sedatives such as phenoparbital sodium; antiemetics such as tonpelitone; and ptylscobromide? Examples include antispasmodics such as lamin; laxatives such as glycerin; antitussive expectorants such as zozolophyllin; and anti-malignant tumor agents such as tegafur.
本発明の坐剤には、単層坐剤、多層坐剤いずれの形態を
も含むものであるが、多層坐剤が特に好ましい。多層坐
剤は2層坐剤、3層坐剤、4層坐剤・・・・・・・・・
とあげることができるが坐剤1ヶの重量が約1.5〜2
.OP程度であることを考えると、2層坐剤が最も製造
が容易である。このため特に2層坐剤においては坐剤先
端部、あるいは基部のどちらか一方を前記油脂性基剤不
溶性色素、特にタール系色素にて着色すれば先端部と基
部の境界部をはっきりと示すことができる。このような
考え方によれば、3層以上の多層坐剤においてすべての
各層にいろいろな色素音用いて着色することも可能では
あるが、各層の区別が可能であればよいわけであり同一
の色素全1つおきに着色することで各層の境界を区別す
ることもできるし、また複数の色調の異なる色素を用い
て1つおきに着色することもできる。Although the suppositories of the present invention include both single-layer suppositories and multi-layer suppositories, multi-layer suppositories are particularly preferred. Multilayer suppositories include 2-layer suppositories, 3-layer suppositories, 4-layer suppositories...
The weight of one suppository is approximately 1.5 to 2.
.. Considering that it is about OP, two-layer suppositories are the easiest to manufacture. For this reason, especially in two-layer suppositories, if either the tip or the base of the suppository is colored with the above-mentioned oil-based base-insoluble dye, especially a tar-based dye, the boundary between the tip and the base can be clearly indicated. Can be done. According to this idea, it is possible to color each layer of a multilayer suppository with three or more layers using various dye tones, but it is fine as long as it is possible to distinguish each layer, and it is preferable to use the same dye. It is possible to distinguish the boundaries of each layer by coloring every other layer, or it is also possible to color every other layer using a plurality of different pigments.
本発明の坐剤、特に多層坐剤は、加熱溶融した油脂性基
剤に前記色素を添加し、均一になるまで混合攪拌後、坐
剤成形容器に注ぎ込み、冷却後、同様の操作を行い第2
層全圧ぎ込み、順次同様の操作全行うことにより製造す
ることができる。The suppositories of the present invention, particularly the multilayer suppositories, are prepared by adding the pigment to a heated and melted oil-based base, mixing and stirring until homogeneous, pouring into a suppository molding container, cooling, and performing the same operation. 2
It can be manufactured by pressing all the layers and sequentially performing all the same operations.
本発明坐剤に用いられる色素は、油脂性基剤とは相溶し
ない。従って本発明坐剤は、該色素の微細粒子が油脂性
基剤中に分散することにより着色されているものである
。このため油脂性基剤中では色素粒子は固化した油脂性
基剤に固定され、移動がおこらず特に多層坐剤の場合、
ある特定の層より他の層への移動が生じないものと思わ
れる。The pigment used in the suppository of the present invention is not compatible with the oily base. Therefore, the suppository of the present invention is colored by dispersing fine particles of the pigment in an oily base. Therefore, in the oily base, the pigment particles are fixed to the solidified oily base and do not move, especially in the case of multilayer suppositories.
It seems that no migration occurs from one particular layer to another.
本発明の坐剤は油脂性基剤中に該油脂性基剤に不溶性の
色素を均一に分散せしめたものであり、これにより1%
に多層坐剤の場合各層の境界面が明瞭となり、製造時の
品質管理の正確さ及び容易さ金増すことができる。また
この色素は油脂性基剤に不溶であるため、他の1−への
移動がなく、長期間安定である。The suppository of the present invention has a pigment insoluble in the oily base uniformly dispersed in the oily base.
In the case of multilayer suppositories, the boundaries between each layer are clear, which increases the accuracy and ease of quality control during manufacturing. Furthermore, since this dye is insoluble in the oil-based base, it does not migrate to other 1- molecules and is stable for a long period of time.
次に実施例を挙げて本発明の詳細な説明するが、本発明
はこれにより限定されるものではない。EXAMPLES Next, the present invention will be described in detail with reference to Examples, but the present invention is not limited thereto.
実施例1
油脂性基剤インカカオ〔花王■、融点37”C)9Q9
95重i%を加熱溶融し、赤色102号1QOO5重i
%添加、混合した後シラスチック製コンテナーに1.7
2あて充填し、淡赤色の単層坐剤を得た。Example 1 Oil-based base Incacao [Kao ■, melting point 37''C) 9Q9
Heat and melt 95 weight i%, red No. 102 1QOO5 weight i
% addition, 1.7% in a silastic container after mixing.
The mixture was filled in two batches to obtain a pale red single-layer suppository.
実施例2
実施例1にて調製した坐剤基剤をシラスチック製コンテ
ナーにQ5F充填し冷却した〇その後、加熱溶融したイ
ンカカオ’i 1.29さらに充填し冷却し先端部が淡
赤色、基部が白色の2層坐剤を得た。Example 2 The suppository base prepared in Example 1 was filled into a Silastic container with Q5F and cooled. After that, heated and melted Inca Cao'i 1.29 was further filled and cooled, so that the tip became light red and the base became pale red. A white two-layer suppository was obtained.
実施例3
油脂性基剤インカカオ〔花王■融点37℃〕99、99
7重f%を加熱溶融し、青色2号0003重量%を加え
混合した。シラスナック製コンテナーに実施例1にて調
製した坐剤基剤052を注入充填し、冷却固化後さらに
加熱溶融させたインカカオのみを052注入充填し、冷
却固化させた。その後上記にて調製した坐剤基剤f 0
.7 F注入充填し、淡赤色、白色、淡青色の3色より
なる多層坐剤を得た。Example 3 Oil-based base Incacao [Kao ■ Melting point 37°C] 99, 99
7wt% by weight was melted by heating, and 3wt% of Blue No. 2 000 was added and mixed. The suppository base 052 prepared in Example 1 was poured into a Silasnac container, and after being cooled and solidified, only Incacao 052, which had been heated and melted, was poured and solidified. Then the suppository base f 0 prepared above
.. 7F was injected and filled to obtain a multilayer suppository consisting of three colors: pale red, white, and pale blue.
実施例4
インカカオ(融点37℃)98997重i%を加熱溶解
し、青色2号音0.0 O3重量%、塩酸ゾプカイン1
重i%加え、混合攪拌し、プラスチック製コンテナーに
0.5F注入充填し、冷却固化する。次いでインカカオ
(融点37℃)86.9重量%を加熱溶融し、酢酸ゾレ
トニソo ンQ 1重量%、アラントイン1. Oi量
係、酢酸設−α−トコフェロール2.0ffif%、酸
化亜鉛xaoi!%を加え、混合攪拌し、先に注入した
シラスナックコンテナーに1.2fさらに注入充填し、
冷却固化し2層坐剤を得た。Example 4 Incacao (melting point 37°C) 98997 wt% was dissolved by heating, blue No. 2 0.0 O3 wt%, zopcaine hydrochloride 1
Add i% by weight, mix and stir, pour into a plastic container at 0.5F, and cool and solidify. Next, 86.9% by weight of incacao (melting point 37°C) was melted by heating, and 1% by weight of zoletnisone acetate, 1% by weight of allantoin, and 1% by weight of zoletnisone acetate were added. Oi amount, α-tocopherol acetate 2.0ffif%, zinc oxide xaoi! %, mix and stir, and pour 1.2f more into the Shirasunak container that was poured earlier.
The mixture was cooled and solidified to obtain a two-layer suppository.
実験1
実施例2及び実施例3にて製造した多/8坐剤を35℃
及び20℃の恒温室に保存し、経日的に着色の変化を観
察した。対照としては実施例2の水溶性色素のかわりに
油溶性色素としてグアイアズレン金柑いた多層坐剤を用
いた。Experiment 1 Poly/8 suppositories produced in Example 2 and Example 3 were heated at 35°C.
The samples were stored in a constant temperature room at 20° C., and changes in coloration were observed over time. As a control, a multilayer suppository containing guaiazulene kumquat as an oil-soluble pigment instead of the water-soluble pigment of Example 2 was used.
結果を第1表に示す。本発明品は対照品に比べて色素の
移動が認められず、安定であった0
第1表
判定規準
m:色素の移動は認めない
+:色素の移動は境界面より5mna以内什;色素の移
動は境界面よりl OInrn以内+++二色素の移動
は境界面よりl Onum以上以上The results are shown in Table 1. The product of the present invention showed no migration of the dye and was stable compared to the control product. Table 1 Judgment Criteria m: No migration of the dye +: Movement of the dye was within 5 mna from the interface; Movement is within l OInrn from the boundary surface +++ Movement of two dyes is at least l Onum from the boundary surface
Claims (1)
不溶性の色素を均一に分散せしめたことを特徴とする坐
剤。1. A suppository made of an oleaginous base, characterized in that an insoluble pigment is uniformly dispersed in the oleaginous base.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3236688A JPH01207229A (en) | 1988-02-15 | 1988-02-15 | Suppository |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3236688A JPH01207229A (en) | 1988-02-15 | 1988-02-15 | Suppository |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01207229A true JPH01207229A (en) | 1989-08-21 |
Family
ID=12356951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3236688A Pending JPH01207229A (en) | 1988-02-15 | 1988-02-15 | Suppository |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01207229A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1161842A (en) * | 1966-05-31 | 1969-08-20 | Ciba Ltd | New Coloured Suppository Compositions, their Manufacture, and their use for the Manufacture of Coloured Suppositories. |
-
1988
- 1988-02-15 JP JP3236688A patent/JPH01207229A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1161842A (en) * | 1966-05-31 | 1969-08-20 | Ciba Ltd | New Coloured Suppository Compositions, their Manufacture, and their use for the Manufacture of Coloured Suppositories. |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5989618A (en) | Anhydrous emulsion and use | |
DE69817010T2 (en) | SPHEROIDS, PROCESS FOR PRODUCING THE SAME AND MEDICINAL PRODUCTS CONTAINING THEM | |
US5453283A (en) | Orally administered solvent-free pharmaceutical preparation with delayed active-substance release, and a method of preparing the preparation | |
JPH0314804B2 (en) | ||
KR20080019022A (en) | Encapsulated cosmetic compositions | |
AU682880B2 (en) | Soft-shelled gelatin encapsulated particles | |
US6309665B2 (en) | Composition with sustained release of active principle, capable of forming a microemulsion | |
NO168405B (en) | suppository | |
CN102871846A (en) | Solid typed cosmetic formulation | |
IL28931A (en) | Delayed release medicinal tablet | |
JPS6144811A (en) | Sustained release diclofenac sodium pharmaceutical | |
JPH01207229A (en) | Suppository | |
EP0999828B1 (en) | Method for producing active agent preparations with controlled release from a matrix | |
JPH0482818A (en) | Production of multicolor powder solid cosmetic | |
EP0239983B1 (en) | Bricks made of pellets | |
US3325472A (en) | Polycyclohexose-polyoxyethyleneglycol suppository bases | |
JPS5883634A (en) | Novel solid pharmacognosical shape for oral administration and manufacture | |
JPH0413019B2 (en) | ||
DE2838387C2 (en) | ||
JP4926515B2 (en) | Multicolor cosmetics | |
US3908003A (en) | Enrobed solid hydrophobic tableting lubricants and compositions | |
Galal et al. | Study of In‐Vitro Release Characteristics of Carbamazepine Extended Release Semisolid Matrix Filled Capsules Based on Gelucires | |
NZ511663A (en) | Process for the manufacture of liquid filled capsules wherein the fill mass is heated and cooled before encapsulation | |
CN100577211C (en) | Transparent oil-in-water microemulsion matrix and preparation method thereof | |
CN103932974A (en) | Ciclopirox olamine vaginal suppository composition and preparation method thereof |